First-line treatment with alemtuzumab for active multiple sclerosis: A nationwide post-marketing survey in Austria

Ferdinand Otto; B Bajer-Kornek; P Rommer; F Leutmezer; C Franta-Elmer; D Oel; C Latzko; Johann Sellner

doi:10.1016/j.jns.2017.08.2242

First-line treatment with alemtuzumab for active multiple sclerosis: A nationwide post-marketing survey in Austria

Ferdinand Otto, B Bajer-Kornek, P Rommer, F Leutmezer, C Franta-Elmer, D Oel, C Latzko, Johann Sellner

Department of Neurology

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	English
Pages (from-to)	796-796
Journal	JOURNAL OF THE NEUROLOGICAL SCIENCES
Volume	381
DOIs	https://doi.org/10.1016/j.jns.2017.08.2242
Publication status	Published - 2017
Event	23rd World Congress of Neurology (WCN) - Kyoto, JAPAN Duration: 16 Sept 2017 → 21 Sept 2017

Access to Document

10.1016/j.jns.2017.08.2242

Cite this

Otto, F., Bajer-Kornek, B., Rommer, P., Leutmezer, F., Franta-Elmer, C., Oel, D., Latzko, C., & Sellner, J. (2017). First-line treatment with alemtuzumab for active multiple sclerosis: A nationwide post-marketing survey in Austria. JOURNAL OF THE NEUROLOGICAL SCIENCES , 381, 796-796. https://doi.org/10.1016/j.jns.2017.08.2242

Otto, Ferdinand ; Bajer-Kornek, B ; Rommer, P et al. / First-line treatment with alemtuzumab for active multiple sclerosis: A nationwide post-marketing survey in Austria. In: JOURNAL OF THE NEUROLOGICAL SCIENCES 2017 ; Vol. 381. pp. 796-796.

@article{08dde0d445ea46dc9831ecdcd96bdd67,

title = "First-line treatment with alemtuzumab for active multiple sclerosis: A nationwide post-marketing survey in Austria",

author = "Ferdinand Otto and B Bajer-Kornek and P Rommer and F Leutmezer and C Franta-Elmer and D Oel and C Latzko and Johann Sellner",

year = "2017",

doi = "10.1016/j.jns.2017.08.2242",

language = "English",

volume = "381",

pages = "796--796",

journal = "JOURNAL OF THE NEUROLOGICAL SCIENCES ",

issn = "0022-510X",

publisher = "Elsevier ",

note = "23rd World Congress of Neurology (WCN) ; Conference date: 16-09-2017 Through 21-09-2017",

}

Otto, F, Bajer-Kornek, B, Rommer, P, Leutmezer, F, Franta-Elmer, C, Oel, D, Latzko, C & Sellner, J 2017, 'First-line treatment with alemtuzumab for active multiple sclerosis: A nationwide post-marketing survey in Austria', JOURNAL OF THE NEUROLOGICAL SCIENCES , vol. 381, pp. 796-796. https://doi.org/10.1016/j.jns.2017.08.2242

First-line treatment with alemtuzumab for active multiple sclerosis: A nationwide post-marketing survey in Austria. / Otto, Ferdinand; Bajer-Kornek, B; Rommer, P et al.
In: JOURNAL OF THE NEUROLOGICAL SCIENCES , Vol. 381, 2017, p. 796-796.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - First-line treatment with alemtuzumab for active multiple sclerosis: A nationwide post-marketing survey in Austria

AU - Otto, Ferdinand

AU - Bajer-Kornek, B

AU - Rommer, P

AU - Leutmezer, F

AU - Franta-Elmer, C

AU - Oel, D

AU - Latzko, C

AU - Sellner, Johann

PY - 2017

Y1 - 2017

U2 - 10.1016/j.jns.2017.08.2242

DO - 10.1016/j.jns.2017.08.2242

M3 - Abstract (Journal)

SN - 0022-510X

VL - 381

SP - 796

EP - 796

JO - JOURNAL OF THE NEUROLOGICAL SCIENCES

JF - JOURNAL OF THE NEUROLOGICAL SCIENCES

T2 - 23rd World Congress of Neurology (WCN)

Y2 - 16 September 2017 through 21 September 2017

ER -

Otto F, Bajer-Kornek B, Rommer P, Leutmezer F, Franta-Elmer C, Oel D et al. First-line treatment with alemtuzumab for active multiple sclerosis: A nationwide post-marketing survey in Austria. JOURNAL OF THE NEUROLOGICAL SCIENCES . 2017;381:796-796. doi: 10.1016/j.jns.2017.08.2242